首页> 外文期刊>International Journal of Cancer =: Journal International du Cancer >Reference ranges for HE4 and CA125 in a large Asian population by automated assays and diagnostic performances for ovarian cancer
【24h】

Reference ranges for HE4 and CA125 in a large Asian population by automated assays and diagnostic performances for ovarian cancer

机译:通过自动测定和诊断卵巢癌的能力,在亚洲大量人口中的HE4和CA125参考范围

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Human epididymis protein 4 (HE4) is a new biomarker for the detection of ovarian cancer. We evaluated the analytical performance of a novel automated HE4 assay and established reference ranges of HE4 and CA125. We also compared the diagnostic performance of both biomarkers for ovarian cancer. Precision performances and linearity of the HE4 assay were assessed. Serum samples from 2,182 healthy and 72 pregnant women were also assayed for HE4 and CA125, and the 95%, 97.5% and 99% reference limits for both markers were calculated. Additionally, sera from 66 ovarian cancer and 257 benign gynecologic disease patients were tested to validate reference ranges and diagnostic performances. The total precision of the HE4 assay was <5% coefficient of variation for most of the levels evaluated. The linearity range of this assay was from 15.0 to 1100.0 pmol/L. The 97.5% upper reference limits for HE4 and CA125 were 33.2 pmol/L (95% confidence interval [CI], 32.2-34.0) and 38.3 U/mL (95% CI, 35.1-41.5), respectively. Using these values as cutoff points, the sensitivity and specificity of HE4 for differentiating ovarian cancer from benign gynecologic diseases and healthy individuals were 90.9% and 94.1%, and those of CA125 were 72.7% and 94.4%. The receiver operating characteristic-area under the curve values of HE4 and CA125 for discriminating ovarian cancer from age-matched control were 0.94 and 0.86, respectively, and they were statistically different (p = 0.0095). The new automated HE4 assay showed good analytical and diagnostic performances. The reference limits established in our study could be used as cutoff levels to facilitate more accurate diagnosis of ovarian cancer in Asian population.
机译:人附睾蛋白4(HE4)是用于检测卵巢癌的新生物标记。我们评估了新型自动HE4分析的分析性能,并确定了HE4和CA125的参考范围。我们还比较了两种生物标记物对卵巢癌的诊断性能。评估了HE4测定的精密度和线性。还对2182名健康女性和72名孕妇的血清样本中的HE4和CA125进行了测定,并计算了两种标记的95%,97.5%和99%的参考限。此外,对来自66名卵巢癌和257名良性妇科疾病患者的血清进行了测试,以验证参考范围和诊断性能。对于大多数评估的水平,HE4分析的总精度<5%变异系数。该测定的线性范围为15.0至1100.0 pmol / L。 HE4和CA125的97.5%上限为33.2 pmol / L(95%置信区间[CI],32.2-34.0)和38.3 U / mL(95%CI,35.1-41.5)。使用这些值作为临界点,HE4区分卵巢癌与良性妇科疾病和健康个体的敏感性和特异性分别为90.9%和94.1%,而CA125的敏感性和特异性分别为72.7%和94.4%。 HE4和CA125曲线值下用于区分卵巢癌和年龄匹配对照组的受试者工作特征区域分别为0.94和0.86,在统计学上有差异(p = 0.0095)。新的自动化HE4分析显示出良好的分析和诊断性能。在我们的研究中建立的参考限值可以用作临界水平,以帮助更准确地诊断亚洲人群的卵巢癌。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号